R21/Matrix-M malaria vaccine candidate: 77% efficacy in Ph2b trial
Positive results from an EDCTP-funded clinical trial in Burkina Faso, published as a preprint with The Lancet, demonstrate that the malaria vaccine candidate R21/Matrix-M is safe, immunogenic and has an efficacy of 77%, exceeding the WHO goal of 75% efficacy for malaria vaccines.
The trial in Burkina Faso was led by the clinical trial investigator, Professor Halidou Tinto of the Institute of Research in Health Sciences (IRSS) in Burkina Faso, as a part of the Multi-Stage Malaria Vaccine Consortium (MMVC). This Europe-Africa malaria vaccine consortium, led by Professor Adrian Hill (University of Oxford) and supported by a €15M grant from EDCTP, aims to develop the first multi-stage vaccine for malaria, designed to target all four life cycle stages of the Plasmodium falciparum parasite. Preparations for a large-scale Phase 3 trial are underway.
Virtual session ‘A new era for malaria control: the role of malaria vaccines’ (18 October 2021)
During the Tenth EDCTP Forum, WHO and EDCTP are organising the virtual plenary session ‘A new era for malaria control: the role of malaria vaccines’. During this session, WHO and partners will share two years of data from the Malaria Vaccine Implementation Programme (MVIP) and explore next steps for the use of the RTS,S vaccine as part of the broader malaria control toolkit.